Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.

Oncology (Williston Park, N.Y.) - 13 May 2020

Wright Kevin M

Abstract excerpt

Evidence for maintenance treatment with PARP inhibitors as the standard of care in the frontline setting for patients with ovarian cancer continues to mount, according to additional analyses from the phase 3 PRIMA trial and the phase 3 PAOLA-1 trial released as part of the virtual platform for the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women's Cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Randomized Controlled Trials as Topic

Share to Recombinational DNA Repair

Share to Treatment Outcome

Source

Identifiers

PMID: 32644177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.PMID 32644177Read ↗

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.Semantic proximity Read ↗

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trialsSemantic proximity Read ↗

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read ↗

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

Making the best of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

First-line PARP inhibition in ovarian cancer - standard of care for all?Semantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity Read ↗

Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.